Multiple myeloma pathophysiology: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==Pathophysiology== | ==Pathophysiology== | ||
*Multiple myeloma arises from post-germinal center [[B lymphocytes]], that are normally involved in production of human [[immunoglobulins]].<ref name="pmid20184542">{{cite journal| author=Agarwal JR, Matsui W| title=Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. | journal=Anticancer Agents Med Chem | year= 2010 | volume= 10 | issue= 2 | pages= 116-20 | pmid=20184542 | doi= | pmc=PMC3033115 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20184542 }} </ref> | *Multiple myeloma arises from post-germinal center [[B lymphocytes]], that are normally involved in production of human [[immunoglobulins]].<ref name="pmid20184542">{{cite journal| author=Agarwal JR, Matsui W| title=Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. | journal=Anticancer Agents Med Chem | year= 2010 | volume= 10 | issue= 2 | pages= 116-20 | pmid=20184542 | doi= | pmc=PMC3033115 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20184542 }} </ref> | ||
* Production of [[cytokine]]s (especially [[Interleukin 6|IL-6]]) by the plasma cells causes much of their localised damage, such as [[osteoporosis]], and creates a microenvironment in which the [[malignant]] cells thrive. [[Angiogenesis]] (the attraction of new blood vessels) is increased. | * Production of [[cytokine]]s (especially [[Interleukin 6|IL-6]]) by the plasma cells causes much of their localised damage, such as [[osteoporosis]], and creates a microenvironment in which the [[malignant]] cells thrive. [[Angiogenesis]] (the attraction of new blood vessels) is increased. | ||
*Increased risk of infection is due to immune deficiency resulting from diffuse [[hypogammaglobulinemia]], which is due to decreased production and increased destruction of normal [[antibody|antibodies]]. | *Increased risk of infection is due to immune deficiency resulting from diffuse [[hypogammaglobulinemia]], which is due to decreased production and increased destruction of normal [[antibody|antibodies]]. | ||
Revision as of 18:00, 18 September 2015
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma pathophysiology On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma pathophysiology |
|
Risk calculators and risk factors for Multiple myeloma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Multiple myeloma arises from post-germinal center B lymphocytes, that are normally involved in production of human immunoglobulins.[1] A chromosomal translocation between the immunoglobulin heavy chain gene and one of many oncogenes leads to dysregulated multiplication of plasma cells. This leads to a localized damage, resulting in punched out bony lesions as well as various organ damage among other symptoms.
Pathophysiology
- Multiple myeloma arises from post-germinal center B lymphocytes, that are normally involved in production of human immunoglobulins.[1]
- Production of cytokines (especially IL-6) by the plasma cells causes much of their localised damage, such as osteoporosis, and creates a microenvironment in which the malignant cells thrive. Angiogenesis (the attraction of new blood vessels) is increased.
- Increased risk of infection is due to immune deficiency resulting from diffuse hypogammaglobulinemia, which is due to decreased production and increased destruction of normal antibodies.
- The produced antibodies are deposited in various organs leading polyneuropathy and various other multiple myeloma associated symptoms.
- Renal failure due to glomerular deposition of amyloid or tubular damage from excretion of light chains called Bence Jones proteins, which can manifest as the Fanconi syndrome (type II renal tubular acidosis).
Genetics
- Genes involved in the pathogenesis of multiple myeloma include heavy chain gene (on the chromosome 14, locus 14q32), chromosome 13, and oncogenes (often 11q13, 4p16.3, 6p21, 16q23 and 20q11).[2]
- A genetic mutation results in dysregulation of the oncogene which is thought to be an important initiating event in the pathogenesis of multiple myeloma.
Gross Pathology
-
Vertebras in multiple myeloma
(Image courtesy of Melih Aktan M.D.) -
Calvarium in multiple myeloma.
(Image courtesy of Melih Aktan M.D.)
Microscopic Pathology
-
![Multiple Myeloma slide showing plasma cells with large nucleus and scant cytoplasm [3]](/images/a/a5/Multiple_Myeloma.jpg)
Multiple Myeloma slide showing plasma cells with large nucleus and scant cytoplasm [3] -
Bone marrow aspiration in multiple myeloma.
(Image courtesy of Melih Aktan M.D.) -
Bone marrow biopsy in multiple myeloma.
(Image courtesy of Melih Aktan M.D.) -
Bone marrow in multiple myeloma.
(Image courtesy of Melih Aktan M.D.) -
Bone marrow in multiple myeloma.
(Image courtesy of Melih Aktan M.D.)
![Multiple Myeloma slide showing plasma cells with large nucleus and scant cytoplasm [3]](/index.php/File:Multiple_Myeloma.jpg)
References
- ↑ 1.0 1.1 Agarwal JR, Matsui W (2010). "Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis". Anticancer Agents Med Chem. 10 (2): 116–20. PMC 3033115. PMID 20184542.
- ↑ Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73. PMID 15509819.
- ↑ http://picasaweb.google.com/mcmumbi/USMLEIIImages